A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
Key Inclusion Criteria:
Key Exclusion Criteria:
Los Angeles, California 90048, United States
Mission Viejo, California 92691, United States
Rochester, Minnesota 55905, United States
Columbia, Missouri 65201, United States
Columbia, Missouri 65201, United States
Williamsburg, Virginia 23188, United States
Fukuoka, Fukuoka 815-8588, Japan
Mizunami-shi, Gifu 509-6134, Japan
Aki-gun, Hiroshima 735-8585, Japan
Fukuyama, Hiroshima 7200001, Japan
Naka-gun, Ibaraki 319-1113, Japan
Sakaide-shi, Kagawa-ken 762-8550, Japan
Sagamihara-shi, Kanagawa 252-0392, Japan
Sakai-shi, Osaka 591-8555, Japan
Hamamatsu, Shizuoka 430-8525, Japan
Chuo-ku, Tokyo 103-0022, Japan
Chuo-ku, Tokyo 104-0031, Japan
Kokubunji-shi, Tokyo 185-0014, Japan
Setagaya-ku, Tokyo 157-0072, Japan
Shibuya-shi, Tokyo 150-0013, Japan
Shinagawa-ku, Tokyo 140-8522, Japan
Toshima-ku, Tokyo 170-0003, Japan
Shimonoseki-shi, Yamaguchi 750-8520, Japan
Kharkiv, 61007, Ukraine
Kharkiv, 61058, Ukraine
Kherson, 73000, Ukraine
Kyiv, 02232, Ukraine
Kyiv, 03038, Ukraine
Kyiv, 03049, Ukraine
Kyiv, 03115, Ukraine
Lutsk, 43005, Ukraine
Vinnytsia, 21001, Ukraine
Vinnytsia, 21018, Ukraine
Corby, Northamptonshire NN18 9EZ, United Kingdom
North Shields, Northumberland NE29 8NH, United Kingdom